Inhibitory effect of p38 mitogen‐activated protein kinase inhibitors on cytokine release from human macrophages

[1]  H. Genant,et al.  A Selective p38α Mitogen-Activated Protein Kinase Inhibitor Reverses Cartilage and Bone Destruction in Mice with Collagen-Induced Arthritis , 2006, Journal of Pharmacology and Experimental Therapeutics.

[2]  I. Viano,et al.  Macrophage‐stimulating protein differently affects human alveolar macrophages from smoker and non‐smoker patients: evaluation of respiratory burst, cytokine release and NF‐κB pathway , 2006, British journal of pharmacology.

[3]  H. Genant,et al.  A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. , 2006, The Journal of pharmacology and experimental therapeutics.

[4]  H. H. Choo,et al.  Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. , 2005, American journal of respiratory and critical care medicine.

[5]  Hui Wang,et al.  p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells. , 2004, Journal of molecular and cellular cardiology.

[6]  P. Barnes.  Mediators of Chronic Obstructive Pulmonary Disease , 2004, Pharmacological Reviews.

[7]  A. Nicholson,et al.  Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes , 2004, Molecular Pharmacology.

[8]  P. Limburg,et al.  Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts , 2004, Annals of the rheumatic diseases.

[9]  R. Pauwels,et al.  Burden and clinical features of chronic obstructive pulmonary disease (COPD) , 2004, The Lancet.

[10]  I. Adcock,et al.  Mitogen-activated protein kinase modulation of nuclear factor-kappaB-induced granulocyte macrophage-colony-stimulating factor release from human alveolar macrophages. , 2004, American journal of respiratory cell and molecular biology.

[11]  P. Barnes.  Alveolar Macrophages as Orchestrators of COPD , 2004, COPD.

[12]  A. Nicholson,et al.  Discovery of BRL 50481, a Selective Inhibitor of Phosphodiesterase 7: In vitro Studies in Human Monocytes, Lung Macrophages and CD8 + T-Lymphocytes , 2004 .

[13]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[14]  P. Barnes,et al.  Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[15]  P. Shah,et al.  Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[16]  G. Johnson,et al.  Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases , 2002, Science.

[17]  P. Jeffery,et al.  The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. , 2002, American journal of respiratory and critical care medicine.

[18]  S. Mackenzie,et al.  Post‐transcriptional regulation of TNF‐α during in vitro differentiation of human monocytes/macrophages in primary culture , 2002, Journal of leukocyte biology.

[19]  P. Barnes,et al.  Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory cell and molecular biology.

[20]  M. Belvisi,et al.  Role of p38 MAP kinase in LPS‐induced airway inflammation in the rat , 2001, British journal of pharmacology.

[21]  Alan D. Lopez.  THE GLOBAL BURDEN OF DISEASE 1990-2020 , 2001 .

[22]  John C. Lee,et al.  SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[23]  Y. Nasuhara,et al.  p38 MAP kinase and MKK‐1 co‐operate in the generation of GM‐CSF from LPS‐stimulated human monocytes by an NF‐κB‐independent mechanism , 2000, British journal of pharmacology.

[24]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[25]  R R Osborn,et al.  SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. , 2000, The Journal of pharmacology and experimental therapeutics.

[26]  P. Jeffery,et al.  Differences and similarities between chronic obstructive pulmonary disease and asthma , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[27]  C. Manthey,et al.  Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. , 1999, Journal of immunology.

[28]  J. Dean,et al.  p38 Mitogen-activated Protein Kinase Regulates Cyclooxygenase-2 mRNA Stability and Transcription in Lipopolysaccharide-treated Human Monocytes* , 1999, The Journal of Biological Chemistry.

[29]  Alan D. Lopez,et al.  The global burden of disease, 1990–2020 , 1998, Nature Medicine.

[30]  J. Barendregt,et al.  Global burden of disease , 1997, The Lancet.

[31]  P. Barnes,et al.  Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. , 1995, Molecular pharmacology.

[32]  James Allen,et al.  Macrophage and monocyte IL-1 beta regulation differs at multiple sites. Messenger RNA expression, translation, and post-translational processing. , 1992, Journal of immunology.